ライフサイエンスコーパス: hepatitis C virus infection

1 Blood donors are routinely screened for hepatitis C virus infection.

2 decades largely because of the prevalence of hepatitis C virus infection.

3 net health benefit for persons screened for hepatitis C virus infection.

4 iated with any of the clinical parameters of hepatitis C virus infection.

5 ency of CCR5Delta32/Delta32 in patients with hepatitis C virus infection.

6 hemophiliacs rather than a susceptibility to hepatitis C virus infection.

7 tem polymorphisms have not been evaluated in hepatitis C virus infection.

8 n combination with interferon-alpha to treat hepatitis C virus infection.

9 and post-OLT sera from 87 OLT patients with hepatitis C virus infection.

10 e therapy as a strategy for the treatment of hepatitis C virus infection.

11 revolutionized care of patients with chronic hepatitis C virus infection.

12 hich is a novel therapy for the treatment of hepatitis C virus infection.

13 fe therapies for the 170 million people with hepatitis C virus infection.

14 iral cytokine, are also less likely to clear hepatitis C virus infection.

15 acting antiviral drugs used to treat chronic hepatitis C virus infection.

16 ed Japanese patients with chronic genotype 1 hepatitis C virus infection.

17 s to an improved management strategy against hepatitis C virus infection.

18 bavirin, is an efficacious approach to treat hepatitis C virus infection.

19 ntributes to poor control and persistence of hepatitis C virus infection.

20 therapeutic intervention in treating chronic hepatitis C virus infection.

21 ase III clinical trials for the treatment of hepatitis C virus infection.

22 ylococcus aureus bacteremia, candidemia, and hepatitis C virus infection.

23 , the alpha-fetoprotein, or the detection of Hepatitis C Virus infection.

24 Steatosis is a frequent complication of hepatitis C virus infection.

25 common reason for liver transplantation was hepatitis C virus infection.

26 and preliminary data on antiviral agents for hepatitis C virus infection.

27 nic liver injury due to hepatitis B virus or hepatitis C virus infection.

28 ses that represents a new concept in chronic hepatitis C virus infection.

29 n humans is strongly associated with chronic hepatitis C virus infection.

30 l of 161 patients were identified with acute hepatitis C virus infection.

31 or assessment in clinical trials for chronic hepatitis C virus infection.

32 therapeutically as an antiviral drug during hepatitis C virus infections.

33 ronic lymphocytic choriomeningitis virus and hepatitis C virus infections.

34 tions, such as HIV-1, hepatitis B virus, and hepatitis C virus infections.

35 e pathogenesis of human immunodeficiency and hepatitis C virus infections.

36 epatitis, especially chronic hepatitis B and hepatitis C virus infections.

37 (seven healthy volunteers, 13 patients with hepatitis C virus infection; 14 men, six women; mean age

38 us infection; 29.1% (95% CI: 23.6-34.5%) for hepatitis C virus infection; 33.9% (95% CI: 24.3-43.5%)

39 n (54.1%, P = 0.001), had lower incidence of hepatitis C virus infection (4.9%, P = 0.001) and longer

40 rrhosis was present in 83% of patients, with hepatitis C virus infection (41%), alcohol (39%), and he

41 or 8, 12, or 24 weeks in patients with acute hepatitis C virus infection a total of 161 patients were

42 Chronic hepatitis C virus infection activates an intrahepatic im

43 isease (adjusted odds ratio, 7.4; P <.0001), hepatitis C virus infection (adjusted odds ratio, 6.1; P

44 Recurrent hepatitis C virus infection after liver transplantation

45 he overall survival of patients with chronic hepatitis C virus infection after orthotopic liver trans

46 djusted for age, race or ethnicity, smoking, hepatitis C virus infection, alcohol use disorders, drug

47 nd hepatitis B virus infection, but not with hepatitis C virus infection, among men of Japanese ances

48 iral drug ribavirin (currently used to treat hepatitis C virus infections, among others) is an RNA vi

49 old-especially those born in the peak era of hepatitis C virus infection and among whites/Caucasians.

50 preclinical candidates for the treatment of hepatitis C virus infection and as probes to study hepat

51 in family that is reported to be involved in hepatitis C virus infection and cell proliferation.

52 adult end-stage renal disease patients with hepatitis C virus infection and compared death rates bet

53 Sixty six patients with chronic hepatitis C virus infection and eligible for inclusion h

54 HSCs are activated during hepatitis C virus infection and may therefore play a rol

55 called mixed cryoglobulinemia and is seen in hepatitis C virus infection and systemic diseases such a

56 the possible pathogenic relationship between hepatitis C virus infection and the nephrotic syndrome t

57 ith hepatitis A virus, hepatitis B virus, or hepatitis C virus infection; and normal human sera), and

58 r with the clinical spectrum associated with hepatitis C virus infection as well as the neuropsychiat

59 easing rapidly worldwide; after treatment of hepatitis C virus infection becomes more widespread, fat

60 type-I IFN, is widely used to treat chronic hepatitis C virus infection, but the broad expression of

61 d in New World primates as a model for human hepatitis C virus infection, but the distribution of GBV

62 through the control of hepatitis B virus and hepatitis C virus infections by vaccination and treatmen

63 Chronic hepatitis C virus infection can cause chronic liver dise

64 Spontaneous resolution of acute hepatitis C virus infection cannot be predicted, and chr

65 In addition, hepatitis C virus infection clearly causes a Sjogren's-s

66 Hepatitis C virus infection confers a 20% to 30% increas

67 t treatment for patients with non-genotype 1 hepatitis C virus infection consists of pegylated interf

68 Hepatitis C virus infection constitutes a serious health

69 Hepatitis C virus infection constitutes a significant he

70 Treatment for hepatitis C virus infection currently consists of pegyla

71 Untreated patients with chronic hepatitis C virus infection had levels of NOS activity a

72 of interferon-free antiviral treatments for hepatitis C virus infection has arrived.

73 In recent years, hepatitis C virus infection has been reported to be typi

74 However, its relationship with therapy for hepatitis C virus infection has not been evaluated.

75 Hepatitis C virus infection has reached epidemic proport

76 Hepatitis C virus infection has recently been recognized

77 Children with chronic hepatitis C virus infection have limited treatment optio

78 antiviral drugs for the treatment of chronic hepatitis C virus infection have reduced mortality and t

79 olicy has not covered for other genotypes of hepatitis C virus infection (HCV) especially for genotyp

80 Recent advances in the treatment of hepatitis C virus infection (HCV) have led to high rates

81 ople is hepatitis B virus (HBV), followed by hepatitis C virus infection (HCV), although nonviral cau

82 n multivariate analysis, injection drug use, hepatitis C virus infection, HIV infection, serum HBsAg

83 pressive gains were made in the treatment of hepatitis C virus infection in difficult-to-treat patien

84 ce to recommend for or against screening for hepatitis C virus infection in high-risk individuals (I

85 ing the relationship of steatosis to chronic hepatitis C virus infection in native and transplanted l

86 ociated with Crohn's disease and progressive hepatitis C virus infection in patients.

87 s after DAA therapy in patients with chronic hepatitis C virus infection in the context of the immune

88 se chain reaction can identify recurrence of hepatitis C virus infection in the liver as early as 5 d

89 These findings indicate that, during acute hepatitis C virus infection in vivo, virus-specific neut

90 and well tolerated in patients with chronic hepatitis C virus infection, including those with compen

91 Hepatitis C virus infection is a disease that disproport

92 k of viral response to interferon therapy of hepatitis C virus infection is associated with blunted i

93 Persistent hepatitis C virus infection is associated with progressi

94 Chronic hepatitis C virus infection is associated with significa

95 Hepatitis C virus infection is associated with worse pat

96 Chronic hepatitis C virus infection is common in the United Stat

97 Hepatitis C virus infection is difficult to differentiat

98 Hepatitis C virus infection is most common among non-Cau

99 In most western countries, hepatitis C virus infection is the predominant cause, an

100 Chronic hepatitis C virus infection is well-recognized as a comm

101 ymptoms are commonly associated with chronic hepatitis C virus infection, its sequelae, and its treat

102 e suggests that genetic factors, gender, and hepatitis C virus infection may play a role.

103 oprotein levels in 746 subjects with chronic hepatitis C virus infection, not currently undergoing tr

104 ly slightly lower than that in patients with hepatitis C virus infection only.

105 otypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completi

106 of lung cavities (P < .001), and absence of hepatitis C virus infection (P = .001).

107 LTX HIV load of >400 copies/mL (P=.016), and hepatitis C virus infection (P=.023).

108 re was an avalanche of new information about hepatitis C virus infection, particularly its relationsh

109 Hepatitis C virus infection persists after liver transpl

110 Hepatitis C virus infection plus a history of heavy alco

111 Hepatitis C virus infections proceed to chronicity in th

112 subset of patients with SMZL associates with hepatitis C virus infection, prompting virus eradication

113 host interactions and protective immunity in hepatitis C virus infection provide an important roadmap

114 In hepatitis C virus infection, replication of the viral ge

115 patients with IFN-alpha2b and ribavirin for hepatitis C virus infection resulted in a profound suppr

116 Newer agents for the treatment of hepatitis C virus infection show promise.

117 particularly in areas of high prevalence of hepatitis C virus infection such as Italy.

118 The recent development of a robust in vitro hepatitis C virus infection system will aid this search.

119 suggest veterans have a higher prevalence of hepatitis C virus infection than nonveterans, possibly b

120 cardiac toxicity related to DOX therapy and hepatitis C virus infection that presumably resulted fro

121 Innate immunity is induced by hepatitis C virus infection through the recognition of v

122 ologic response rates in patients with acute hepatitis C virus infection, thus preventing development

123 han half of patients with genotype 1 chronic hepatitis C virus infection treated for 48 weeks.

124 To investigate whether patients with hepatitis C virus infection treated with IFN-alpha kille

125 BACKGROUND & AIMS: Patients with recurrent hepatitis C virus infection treated with pegylated inter

126 Hepatitis C virus infection was defined as the presence

127 The incidence of hepatitis C virus infection was higher in recipients wit

128 Hepatitis C virus infection was present in 25 of 31 (81%

129 Hepatitis C virus infection was reported as a possible r

130 sion during human immunodeficiency virus and hepatitis C virus infection, we explored whether such a

131 The clinical parameters of hepatitis C virus infection were compared between carrie

132 m costs of treatment and diagnostics to cure hepatitis C virus infection were estimated at US$171-360

133 520 treatment-naive patients with genotype 1 hepatitis C virus infection were randomly assigned to re

134 ) to interferon-based treatments for chronic hepatitis C virus infection, whereas Asian race was asso

135 emain the cornerstone of therapy for chronic hepatitis C virus infection, which affects nearly 170 mi

136 clinical relevance in hepatitis B virus and hepatitis C virus infections, which can cause acute and

137 report a case series of three patients with hepatitis C virus infection who all presented with sever

138 publications highlighted the association of hepatitis C virus infection with lymphoproliferative dis

139 splant recipient who acquired posttransplant hepatitis C virus infection with rapid histological prog

140 east 20 years of age with chronic genotype 1 hepatitis C virus infection with serum hepatitis C virus

141 New Zealand of 197 patients with genotype 1 hepatitis C virus infection, with or without compensated